World's Best Scientists 2026 revealed!
Julio S. G. Montaner

Julio S. G. Montaner

Award Badge
Immunology
Canada
2026
Award Badge
Medicine
Canada
2023

D-Index & Metrics

Immunology

D-Index
136
Citations
88174
World Ranking
181
National Ranking
2

Medicine

D-Index
137
Citations
88449
World Ranking
1878
National Ranking
68

Research.com Recognitions

  • 2026 - Research.com Immunology in Canada Leader Award
  • 2025 - Research.com Immunology in Canada Leader Award
  • 2023 - Research.com Medicine in Canada Leader Award
  • 2009 - Fellow of the Royal Society of Canada Academy of Science

Overview

Julio S. G. Montaner is affiliated with the University of British Columbia in Canada. Their primary field of study is Medicine, with a focused expertise in Infectious Diseases, Epidemiology, Virology, Emergency Medicine, and Public Health, Environmental and Occupational Health.

Montaner's research has extensively covered topics related to HIV/AIDS and COVID-19. These main topics include:

  • HIV/AIDS Research and Interventions
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • COVID-19 Clinical Research Studies
  • HIV-related health complications and treatments
  • Opioid Use Disorder Treatment

Their publication record includes a significant number of papers, with notable examples such as:

  • "Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results," 2020, The Journal of Infectious Diseases
  • "Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults," 2021, The Journal of Infectious Diseases
  • "Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society-USA Panel," 2020, UNC Libraries
  • "Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy," 2022, npj Vaccines
  • "Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study," 2021, BMJ Open

Montaner has frequently collaborated with several co-authors, including:

  • Rolando Barrios
  • Viviane D. Lima
  • Zabrina L. Brumme
  • Chanson J. Brumme
  • Marc G. Romney

Their work has been published notably in venues such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Journal of Infectious Diseases
  • AIDS
  • PLoS ONE
  • Clinical Infectious Diseases

Julio S. G. Montaner was recognized as a Fellow of the Royal Society of Canada in 2009 by the Academy of Science.

Best Publications

  • Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

    Richard K. Sterling;Eduardo Lissen;Eduardo Lissen;Nathan Clumeck;Ricard Sola

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

    Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

    Jacob P. Lalezari;Keith Henry;Mary O'Hearn;Julio S.G. Montaner

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy

    Robert S. Hogg;Katherine V. Heath;Benita Yip;Kevin J. P. Craib

  • A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

    Julio S. G. Montaner;Peter Reiss;David Cooper;Stefano Vella

  • Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy

    Robert S. Hogg;Benita Yip;Keith J. Chan;Evan Wood

  • Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of the International AIDS Society—USA Panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

    Julio S.G. Montaner;Julio S.G. Montaner;Julio S.G. Montaner;Viviane D. Lima;Viviane D. Lima;Rolando Barrios;Benita Yip

  • Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

    Steffanie A. Strathdee;David M. Patrick;Sue L. Currie;Peter G. A. Cornelisse

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

    Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients

    Hélène C F Côté;Zabrina L Brumme;Kevin J P Craib;Christopher S Alexander

  • The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

    Julio S. G. Montaner;Robert Hogg;Evan Wood;Thomas Kerr

  • Validating a Shortened Depression Scale (10 Item CES-D) among HIV-Positive People in British Columbia, Canada

    Wendy Zhang;Nadia O’Brien;Jamie I. Forrest;Kate A. Salters

Frequent Co-Authors

Evan Wood
Evan Wood University of British Columbia
Thomas Kerr
Thomas Kerr University of British Columbia
Robert S. Hogg
Robert S. Hogg Simon Fraser University
Viviane D. Lima
Viviane D. Lima University of British Columbia
Mark W. Tyndall
Mark W. Tyndall University of British Columbia
Benita Yip
Benita Yip University of British Columbia
P. Richard Harrigan
P. Richard Harrigan University of British Columbia
Michael V. O'Shaughnessy
Michael V. O'Shaughnessy University of California, San Francisco
Martin T. Schechter
Martin T. Schechter University of British Columbia
Brandon D. L. Marshall
Brandon D. L. Marshall Brown University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related degrees in nursing can open diverse career pathways. Many professionals explore accelerated programs to fast-track their careers, such as accelerated FNP programs. These programs are designed for individuals aiming to become Family Nurse Practitioners (FNP) with a strong clinical foundation.

Transitioning from an FNP to a more specialized role like an acute care nurse practitioner requires additional credentials. Obtaining acute care NP certification is essential for those looking to work in high-acuity settings where advanced immunology knowledge is critical.

For individuals starting fresh in healthcare, online ABSN programs for non nurses provide an accessible entry point to the nursing field. These accelerated programs are ideal for career changers passionate about immunology and patient care.

Compensation is often a key consideration. Understanding how much does a DNP make can help guide decisions about advanced degrees and specialization zones in immunology-related nursing careers, ensuring alignment with both professional goals and financial expectations.

Best Scientists Citing Julio S. G. Montaner

Trending Scientists

Recently Published Articles